Cargando…

Metronomic Chemotherapy

SIMPLE SUMMARY: The present article reviews the state of the art of metronomic chemotherapy use to treat the principal types of cancers, namely breast, non-small cell lung cancer and colorectal ones, and of the most recent progresses in understanding the underlying mechanisms of action. Areas of nov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cazzaniga, Marina Elena, Cordani, Nicoletta, Capici, Serena, Cogliati, Viola, Riva, Francesca, Cerrito, Maria Grazia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125766/ https://www.ncbi.nlm.nih.gov/pubmed/34066606 http://dx.doi.org/10.3390/cancers13092236

Ejemplares similares

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
por: Cazzaniga, Marina Elena, et al.
Publicado: (2022)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
por: Pepe, F. F., et al.
Publicado: (2022)

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
por: Capici, Serena, et al.
Publicado: (2022)

Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation
por: Scagliotti, Arianna, et al.
Publicado: (2022)

Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)

Head and neck cancer: metronomic chemotherapy
por: De Felice, Francesca, et al.
Publicado: (2015)

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells
por: Cordani, Nicoletta, et al.
Publicado: (2023)

Metronomic Chemotherapy in Prostate Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2022)

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?
por: Cazzaniga, M. E., et al.
Publicado: (2017)

The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data
por: Capici, Serena, et al.
Publicado: (2021)

Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors
por: Muraro, Elena, et al.
Publicado: (2023)

Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study
por: Zeppellini, Annalisa, et al.
Publicado: (2021)

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?
por: Cazzaniga, Marina Elena, et al.
Publicado: (2019)

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study
por: Cerrito, Maria Grazia, et al.
Publicado: (2018)

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
por: Cazzaniga, M. E., et al.
Publicado: (2021)

Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review
por: Parshad, Shruti, et al.
Publicado: (2022)

Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic
por: Russo, Selena, et al.
Publicado: (2022)

Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study
por: Terraneo, Marco, et al.
Publicado: (2022)

Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience
por: Simsek, Cem, et al.
Publicado: (2019)

Metronomic Chemotherapy in Pediatric Oncology: From Preclinical Evidence to Clinical Studies
por: Banchi, Marta, et al.
Publicado: (2022)

Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O.G., et al.
Publicado: (2009)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

Metronomic palliative chemotherapy in maxillary sinus tumor
por: Patil, Vijay M., et al.
Publicado: (2016)

Metronomic chemotherapy for triple negative breast cancer?
por: Di Desidero, Teresa, et al.
Publicado: (2016)

Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer
por: Liu, Jiaxuan, et al.
Publicado: (2022)

Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives
por: Panthi, Vijay Kumar, et al.
Publicado: (2023)

Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects
por: Pilla, Lorenzo, et al.
Publicado: (2020)

Effectiveness of metronomic chemotherapy in a child with medulloblastoma: A case report
por: Lygina, Elena, et al.
Publicado: (2023)

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman Andrés, et al.
Publicado: (2017)

An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective
por: Cordani, Nicoletta, et al.
Publicado: (2023)

Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas
por: Sheng Sow, Heng, et al.
Publicado: (2013)

Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature
por: Carcamo, Benjamin, et al.
Publicado: (2022)

Can a rational design for metronomic chemotherapy dosing be devised?
por: Maraveyas, A, et al.
Publicado: (2005)

Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
por: Dickinson, P D, et al.
Publicado: (2012)

Use of metronomic chemotherapy in the management of a cat with abdominal haemangiosarcoma
por: Yee-Ka Cheng, Katrina, et al.
Publicado: (2018)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
por: Maharjan, Ruby, et al.
Publicado: (2019)

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
por: Kim, Do Young
Publicado: (2017)

Metronomic Chemotherapy for Palliative Treatment of Malignant Oral Tumors in Dogs
por: Milevoj, Nina, et al.
Publicado: (2022)

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
por: Al-Sukhun, Sana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_andekch3ig7rgminfd6q3d1gig